<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366532">
  <stage>Registered</stage>
  <submitdate>27/06/2014</submitdate>
  <approvaldate>14/07/2014</approvaldate>
  <actrnumber>ACTRN12614000747628</actrnumber>
  <trial_identification>
    <studytitle>A Within-Subject Randomized Controlled Trial on the Effects of Phenytoin on Social Cognition and Behaviour in Males aged 16 Years and Older with Autism Spectrum Disorders</studytitle>
    <scientifictitle>Do Males age 16 Years and Older with Autism Spectrum Disorders on a single dose course of Phenytoin (compared to a placebo) show an effect on Social Cognition and Behaviour?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013771</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Autism Spectrum Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Autistic spectrum disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants receive both treatments in a random order. Participants are randomised to receive either a single dose oral administration of 4mg syrup of Phenytoin or Placebo, followed by a two week wash-out period and then a single dose administration of 4mg syrup of Phenytoin or Placebo.</interventions>
    <comparator>Single dose oral administration of 4mg syrup of Placebo </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Improved social cognition as assessed by the Eye-Gaze Movie Scene Task - duration (total milliseconds spent fixating on the face region) and fixation count (number of times a participant fixated toward a face region).</outcome>
      <timepoint>45 minutes after each single dose administration</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Improved accuracy and speed of identification of the correct emotion from faces as assessed by the Reading the Mind in the Eyes Test (RMET) and the Speeded Face Expression Recognition Task.</outcome>
      <timepoint>45 minutes after each single dose administration</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Increased Heart Rate Variability assessed by the Polar RS800CX heart rate monitoring system</outcome>
      <timepoint>45 minutes after each single dose administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Improved capacity to correctly respond to social cues as assessed by the Social Ball-tossing Game. </outcome>
      <timepoint>45 minutes after each single dose administration</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Meet DSM-IV-TR criteria for Autistic Disorder, Pervasive Developmental Disorder-Not Otherwise Specified or Aspergers Disorder </inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Severe depression, with suicidal thoughts and/or actions; Severe cardiovascular problems; Kidney or Liver problems; Allergies to barbiturates or any other anticonvulsant medicine; Allergies to foods, preservatives or dyes that may be contained in the syrup; Psychosis; Smoke more than 15 cigarettes a day; Phenytoin hypersensitivity; Pregnancy or lactation; High blood sugar levels

Concomitant medications that exclude participants: lcuronium, antineoplastic agents, amiodarone, amphotericin B, azapropazone, azoles, capecitabine [or its metabolite fluorouracil (5FU)], carbamazepine, ciprofloxacin, chloramphenicol, chlordiazepoxide, chlorpropamide, cimetidine, clopidrogel, clozapine, corticosteroids, coumarin anticoagulants, cyclosporine, diazepam, diazoxide, dicumarol, digitoxin, diltiazem, disulfiram, doxycycline, erythromycin, felbamate, fluconazole, fluorouracil, fluoxetine, folic acid, frusemide, fluvoxamine, glibenclamide, H2-antagonists, halothane, isoniazid, itraconazole, ketoconazole, lamotrigine, methadone, methylphenidate, miconazole, nelfinavir, nicardipine, nimodipine, nifedipine, oestrogens, omeprazole, pancuronium, paroxetine, phenobarbitone, phenothiazines, phenylbutazone, praziquantel, quinidine, reserpine, rifampicin, salicylates, sertraline, sodium valproate, succinimides (ethosuximide, methsuximide, phensuximide), sucralfate, sulfonamides, teniposide, tetracycline, ticlopidine, theophylline, tolbutamide, trazodone, valproic acid, verapamil, vecuronium, vigabatrin, viloxazine; Hypericum perforatum (St John's wort); Antacid preparations containing calcium; Vitamin D

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants are assigned to sequential treatment packs labelled with a unique study number. Neither participants nor research staff will be aware of the group allocation.</concealment>
    <sequence>Allocation follows a computer-generated randomisation schedule with balanced variable blocks, prepared by the pharmacist. Each re-packed treatment contains one active and one identical and matched placebo syrup. The pharmacist will hold the randomisation code.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>14/07/2014</anticipatedstartdate>
    <actualstartdate>23/04/2015</actualstartdate>
    <anticipatedenddate>30/12/2015</anticipatedenddate>
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2046 - Abbotsford</postcode>
    <postcode>2131 - Ashfield</postcode>
    <postcode>2041 - Balmain</postcode>
    <postcode>2137 - North Strathfield</postcode>
    <postcode>2132 - Croydon</postcode>
    <postcode>2042 - Newtown</postcode>
    <postcode>2040 - Leichhardt</postcode>
    <postcode>2045 - Haberfield</postcode>
    <postcode>2204 - Marrickville</postcode>
    <postcode>2130 - Summer Hill</postcode>
    <postcode>2007 - Broadway</postcode>
    <postcode>2560 - Campbelltown</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>The University of Sydney
College Street, University of Sydney NSW 2006
</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Autres PTYLD</fundingname>
      <fundingaddress>Autres PTYLD
P.O. Box 680
Maroochydore
Queensland 4558</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the trial is to conduct the first study of the impact of Phenytoin administration (4mg) on key mechanisms involved in social communication in youth aged 16 years and older with Autism Spectrum Disorders. We hypothesize that Phenytoin will, in comparison to an identical and matched placebo: increase gaze duration and fixations to key face regions, improve accuracy and the speed of identification of facial emotion recognition, increase heart rate variability, and improve accuracy of response to social cues.</summary>
    <trialwebsite>http://sydney.edu.au/bmri/patient-services/autism-clinic-translational-research/clinical-studies.php</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Sydney</ethicname>
      <ethicaddress>Human Ethics Office
Margaret Telfer Building (K07)
University of Sydney
NSW 2006</ethicaddress>
      <ethicapprovaldate>12/11/2013</ethicapprovaldate>
      <hrec>2013/771</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Adam Guastella</name>
      <address>Brain and Mind Research Institute 
100 Mallett Street
Camperdown
NSW 2050</address>
      <phone>61293510539</phone>
      <fax />
      <email>adam.guastella@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christine Song</name>
      <address>Brain and Mind Research Institute 
94 Mallett Street
Camperdown
NSW 2050</address>
      <phone>61 2 9351 0940</phone>
      <fax />
      <email>yun.song@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Adam Guastella</name>
      <address>Brain and Mind Research Institute 
100 Mallett Street
Camperdown
NSW 2050</address>
      <phone>61293510539</phone>
      <fax />
      <email>adam.guastella@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Tiffany Sia</name>
      <address>Brain and Mind Research Institute
94 Mallett Street
Camperdown
NSW 2050</address>
      <phone>61 2 9114 4230</phone>
      <fax />
      <email>tiffany.sia@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>